Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?

Am J Kidney Dis. 2005 Mar;45(3):607-9. doi: 10.1053/j.ajkd.2005.01.011.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Editorial

MeSH terms

  • Aspirin / administration & dosage
  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol / blood
  • Chronic Disease
  • Disease Progression
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Kidney Diseases / blood
  • Kidney Diseases / complications*
  • Kidney Diseases / surgery
  • Kidney Diseases / therapy
  • Kidney Transplantation / statistics & numerical data
  • Peritoneal Dialysis / statistics & numerical data
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Renal Dialysis / statistics & numerical data
  • Research Design
  • Simvastatin / adverse effects
  • Simvastatin / therapeutic use*
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Cholesterol
  • Simvastatin
  • Aspirin